Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Treatment Of Fabry Disease: Outcome Of A Comparative Trial With Agalsidase Alfa Or Beta At A Dose Of 0.2 Mg/kg

A. Vedder, G. Linthorst, G. Houge, J. E. Groener, Els E. Ormel, B. Bouma, J. M. Aerts, A. Hirth, C. Hollak
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Background Two different enzyme preparations, agalsidase alfa (ReplagalTM, Shire) and beta (FabrazymeTM, Genzyme), are registered for treatment of Fabry disease. We compared the efficacy of and tolerability towards the two agalsidase preparations administered at identical protein dose in a randomized controlled open label trial. Methodology/Principal Findings Thirty-four Fabry disease patients were treated with either agalsidase alfa or agalsidase beta at equal dose of 0.2 mg/kg biweekly. Primary endpoint was reduction in left ventricular mass after 12 and 24 months of treatment. Other endpoints included occurrence of treatment failure (defined as progression of cardiac, renal or cerebral disease), glomerular filtration rate, pain, anti-agalsidase antibodies, and globotriaosylceramide levels in plasma and urine. After 12 and 24 months of treatment no reduction in left ventricular mass was seen, which was not different between the two treatment groups. Also, no differences in glomerular filtration rate, pain and decline in globotriaosylceramide levels were found. Antibodies developed only in males (4/8 in the agalsidase alfa group and 6/8 in the agalsidase beta group). Treatment failure within 24 months of therapy was seen in 8/34 patients: 6 male patients (3 in each treatment group) and 2 female patients (both agalsidase alfa). The occurrence of treatment failures did not differ between the two treatment groups; χ2 = 0.38 p = 0.54. Conclusion Our study revealed no difference in reduction of left ventricular mass or other disease parameters after 12 and 24 months of treatment with either agalsidase alfa or beta at a dose of 0.2 mg/kg biweekly. Treatment failure occurred frequently in both groups and seems related to age and severe pre-treatment disease. Trial Registration International Standard Randomized Clinical Trial ISRCTN45178534
This paper references
Fabry's Disease: Alpha-Galactosidase Deficiency
J. Kint (1970)
A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.
K. Lee (2003)
Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study.
D. Lévy (1987)
Long- Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease
Wr Wilcox (2004)
Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease
R. Schiffmann (2003)
Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran.
A. J. Apperloo (1996)
Clinical benefit of enzyme replacement therapy in Fabry disease.
F. Breunig (2006)
Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry's disease
Cm Eng (2001)
The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001
R. C. Scriver (2001)
A Simple Method for the Isolation and Purification of Total Lipids from Animal Tissues
J Folch (1957)
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
R. Schiffmann (2006)
Recombinant Enzyme Therapy for Fabry Disease: Absence of Editing of Human α-Galactosidase A mRNA
D. Blom (2003)
Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement.
V. Palmieri (1999)
Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
R. Mignani (2004)
Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease.
R. Hopkin (2003)
Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
L. Spinelli (2004)
Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.
R. Brady (1967)
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females
K. Macdermot (2001)
Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.
R. Schiffmann (2000)
The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy
C. Whybra (2004)
Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice
H. Sakuraba (2006)
Improvement of Cardiac Function During Enzyme Replacement Therapy in Patients With Fabry Disease: A Prospective Strain Rate Imaging Study
F. Weidemann (2003)
Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease
L. Spinelli (2004)
Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)
B. Hoffmann (2005)
Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease.
F. Gaspari (1998)
Enzyme replacement therapy for Fabry disease: lessons from two α-galactosidase A orphan products and one FDA approval
R. Desnick (2004)
Monitoring enzyme replacement therapy in Fabry disease—Role of urine globotriaosylceramide
P. D. Whitfield (2005)
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.
C. Eng (2001)
α-Galactosidase A deficiency. Fabry disease
R. Desnick (2001)
Enzyme replacement therapy and renal function in 201 patients with Fabry disease.
A. Schwarting (2006)
Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene.
I. Redonnet-Vernhet (1996)
Pediatric Fabry Disease
M. Ries (2005)
Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.
G. Linthorst (2004)
A simple method for the isolation and purification of total lipides from animal tissues.
J. Folch (1957)
De ziekte van Fabry : op weg naar een behandeling
GE Linthorst (2000)
Comparative evaluation of α-galactosidase A infusions for treatment of Fabry disease
R. Hopkin (2003)
Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
C. Eng (2001)
LongTerm Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease
WR Wilcox (2004)
Enzyme replacement therapy in Fabry disease: a randomized controlled trial.
R. Schiffmann (2001)
2001) a-Galactosidase A Deficiency: Fabry disease The metabolic and molecular bases of inherited disease 8th ed Vol 3
Rj Desnick
Fabry disease
William J. L. Cable (1982)
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
W. Wilcox (2004)
FDA briefing report Replagal
Enzyme-replacement therapy for AndersonFabry disease
GM Pastores (2001)
Enzyme replacement in Anderson-Fabry disease
B. Bengtsson (2003)
Rapid method of preparation of lysoglycosphingolipids and their confirmation by delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
T. Taketomi (1996)
Fabry disease: overall effects of agalsidase alfa treatment
M. Beck (2004)
Agalsidase-Beta Therapy for Advanced Fabry Disease
M. Banikazemi (2007)
Pediatric Fabry Disease. Pediatrics
M Ries (2005)

This paper is referenced by
Clinical characterisation of cardiac involvement in Anderson-Fabry Disease
J. Shah (2016)
Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors
Dawn A. Laney (2013)
Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies
J. Aerts (2011)
Fabry disease: studies on diagnosis, screening and patients’ perspectives
M. Bouwman (2012)
A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease.
D. Hughes (2013)
Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype-phenotype expression.
C. Paliouras (2015)
Agalsidase Beta Clinical Trials and Long Term Experience
C. Prada (2010)
Gene Therapy for Fabry Disease: A Review of the Literature
A. P. Ruiz de Garibay (2013)
Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases
Doo-Byoung Oh (2015)
Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative.
S. Sirrs (2010)
Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
B. Oqvist (2009)
Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature
O. Lidove (2010)
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
M. Arends (2018)
Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease
J. Marshall (2010)
Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.
R. Desnick (2012)
Vasculopathy in patients with Fabry disease: current controversies and research directions.
S. Rombach (2010)
Fabry disease, enzyme replacement therapy and the significance of antibody responses
P. Deegan (2011)
Serial analysis of cardiopulmonary fitness and echocardiography in patients with Fabry disease undergoing enzyme replacement therapy
S Tuan (2020)
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
S. Rombach (2013)
Potential Factors Influencing Treatment Outcomes
G. Linthorst (2010)
Enzyme Replacement Therapy for Fabry Disease
R. Schaefer (2012)
Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease?
C. Moura (2013)
Cost-effectiveness of Enzyme Replacement Therapy for Fabry Disease
S. Rombach (2012)
Best Practice & Research Clinical Endocrinology & Metabolism
Nora Seydelmann (2015)
Il follow-up cardiologico nel paziente con malattia di Fabry
F. Pieruzzi (2010)
Cost-effectiveness of enzyme replacement therapy for Fabry disease
S. Rombach (2013)
The Fabry cardiomyopathy - diagnostic approach and current treatment.
F. Weidemann (2015)
Stroke and Fabry disease
M. Viana-Baptista (2011)
Fabry Disease: Treatment and diagnosis
P. Rozenfeld (2009)
Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
J. Meschia (2014)
Actualités sur la maladie de Fabry : un diagnostic plus précoce pour un traitement plus efficace
Olivier Lidove (2009)
Management of Fabry Disease with Agalsidase Treatment
Guillem Pintos-Morell (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar